$GRVE
Groove Botanicals Inc

2024 Q1 Form 10-Q Financial Statement

#000117152024000017 Filed on January 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q3 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.43K $16.96K
YoY Change -8.78%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $24.91K $124.0K
YoY Change -45.26%
Operating Profit -$24.91K -$124.0K
YoY Change -45.26%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.500K -$2.250K
YoY Change -95.54%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$27.41K -$77.15K
YoY Change -73.03% -424.89%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 58.64M shares 58.64M shares 58.48M shares
Diluted Shares Outstanding 58.64M shares 58.48M shares

Balance Sheet

Concept 2024 Q1 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.690K
YoY Change
Cash & Equivalents $1.688K $2.846K $2.366K
Short-Term Investments
Other Short-Term Assets $450.00
YoY Change
Inventory
Prepaid Expenses $454.00 $352.00
Receivables $25.00
Other Receivables
Total Short-Term Assets $2.142K $3.223K
YoY Change -57.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.142K $3.223K
Total Long-Term Assets $0.00 $0.00
Total Assets $2.142K $3.223K
YoY Change -57.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.17K
YoY Change
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $762.7K $642.3K
YoY Change 65.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $762.7K $642.3K
Total Long-Term Liabilities $0.00
Total Liabilities $762.7K $642.3K
YoY Change 65.71%
SHAREHOLDERS EQUITY
Retained Earnings -$34.85M -$34.63M
YoY Change 1.25%
Common Stock $59.64K $58.64K
YoY Change 3.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$760.6K -$639.1K -$557.0K
YoY Change
Total Liabilities & Shareholders Equity $2.142K $3.223K
YoY Change -57.01%

Cashflow Statement

Concept 2024 Q1 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$27.41K -$77.15K
YoY Change -73.03% -424.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$30.08K -$32.76K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.62K $30.56K
YoY Change
NET CHANGE
Cash From Operating Activities -30.08K -$32.76K
Cash From Investing Activities 0.000
Cash From Financing Activities 29.62K $30.56K
Net Change In Cash -460.0 -$2.200K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$30.08K -$32.76K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000918573
CY2022Q3 grve Consulting Expense
ConsultingExpense
usd
grve Consulting Expense
ConsultingExpense
usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
grve Repayment Of Convertible Debt
RepaymentOfConvertibleDebt
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-23476
dei Entity Registrant Name
EntityRegistrantName
GROOVE BOTANICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1168832
dei Entity Address Address Line1
EntityAddressAddressLine1
310 Fourth Avenue South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 7000
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55415
dei City Area Code
CityAreaCode
(612)
dei Local Phone Number
LocalPhoneNumber
315-5068
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58643062 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2846 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4566 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
352 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
390 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
3223 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
4982 usd
CY2023Q3 us-gaap Assets
Assets
3223 usd
CY2023Q1 us-gaap Assets
Assets
4982 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
44940 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
44489 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
19678 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
14678 usd
CY2023Q3 grve Related Party Payable Current
RelatedPartyPayableCurrent
368442 usd
CY2023Q1 grve Related Party Payable Current
RelatedPartyPayableCurrent
301100 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
100000 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
100000 usd
CY2023Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
109235 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
642295 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
460267 usd
CY2023Q3 us-gaap Liabilities
Liabilities
642295 usd
CY2023Q1 us-gaap Liabilities
Liabilities
460267 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58643062 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58643062 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57643062 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57643062 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
58643 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
57643 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33932511 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33903511 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34630434 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34416648 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-639072 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-455285 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3223 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4982 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19434 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21305 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36193 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39973 usd
CY2023Q3 grve Rent
Rent
4644 usd
CY2022Q3 grve Rent
Rent
4581 usd
grve Rent
Rent
9288 usd
grve Rent
Rent
8508 usd
CY2023Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
828 usd
CY2022Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
19611 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
24070 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
38169 usd
grve Consulting Expense
ConsultingExpense
30000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
24906 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
45497 usd
us-gaap Operating Expenses
OperatingExpenses
99551 usd
us-gaap Operating Expenses
OperatingExpenses
86650 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24906 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45497 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-99551 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-86650 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
21109 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
61890 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-31773 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
52756 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
25000 usd
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2500 usd
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3735 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7806 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
513 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
734 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2500 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56104 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8794 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-27406 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-101601 usd
us-gaap Net Income Loss
NetIncomeLoss
-104551 usd
us-gaap Net Income Loss
NetIncomeLoss
-77856 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-101601 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77856 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58643062 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58643062 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52193062 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52193062 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58561095 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58561095 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52061914 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52061914 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-454935 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
23745 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-431190 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-101601 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-532791 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-455285 usd
CY2023Q2 grve Issuance Of Stock For Consulting Value
IssuanceOfStockForConsultingValue
30000 usd
CY2023Q2 grve Accrual Of Preferred Dividends To Related Party
AccrualOfPreferredDividendsToRelatedParty
-54618 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-77145 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-557048 usd
CY2023Q3 grve Accrual Of Preferred Dividends To Related Party
AccrualOfPreferredDividendsToRelatedParty
-54618 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-27406 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-639072 usd
us-gaap Net Income Loss
NetIncomeLoss
-104551 usd
us-gaap Net Income Loss
NetIncomeLoss
-77856 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
61890 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-52756 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
25000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
30000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-5000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-7806 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
24000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
24000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
80 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-210 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-38 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-483 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45062 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62109 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
45393 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
151000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
2051 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
4000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
59650 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
70350 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43342 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1720 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45109 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4566 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48534 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2846 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3425 usd
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
the Corporation split their shares One (1) for Three Hundred (300).
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_z9Eaq6oVLIUi" style="font: 10pt Times New Roman,serif; margin: 2pt 0 0"><span id="xdx_862_zh46ZQlEyvG8">Use of Estimates</span></p> <p style="font: 10pt Times New Roman,serif; margin: 0 1.45pt 0.35pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman,serif; margin: 0 1.45pt 0.35pt 0; text-align: justify"> </p>
us-gaap Net Income Loss
NetIncomeLoss
-104551 usd
us-gaap Net Income Loss
NetIncomeLoss
-77856 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34630434 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34416648 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
45189 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
44940 usd
CY2023Q3 grve Related Party Payment Outstanding
RelatedPartyPaymentOutstanding
368442830 usd
CY2023Q1 grve Related Party Payment Outstanding
RelatedPartyPaymentOutstanding
301100 usd
us-gaap Payments To Employees
PaymentsToEmployees
48000 usd
CY2022Q2 grve Related Party Debt
RelatedPartyDebt
125000 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2022Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
164774 usd
CY2023 grve Repayment Of Convertible Debt
RepaymentOfConvertibleDebt
139650 usd
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
74876 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2023Q3 grve Remaining Note Principal Balance
RemainingNotePrincipalBalance
100000 usd
CY2023Q1 grve Remaining Note Principal Balance
RemainingNotePrincipalBalance
100000 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2023Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
500000 usd
CY2023Q3 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
5000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000 usd
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2500000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58643062 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58643062 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57643062 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57643062 shares
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
grve Verbal Lease Agreement Description
VerbalLeaseAgreementDescription
Company has a month-to-month verbal lease agreement with the landlord, in which the Company is obligated to pay $1,200 on a monthly basis.
CY2023Q3 grve Remaining Note Principal Balance
RemainingNotePrincipalBalance
100000 usd
CY2023Q1 grve Remaining Note Principal Balance
RemainingNotePrincipalBalance
100000 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd

Files In Submission

Name View Source Status
grve-20230930_pre.xml Edgar Link unprocessable
0001171520-24-000017-index-headers.html Edgar Link pending
0001171520-24-000017-index.html Edgar Link pending
0001171520-24-000017.txt Edgar Link pending
0001171520-24-000017-xbrl.zip Edgar Link pending
eps11092_grve.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grve-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
grve-20230930_cal.xml Edgar Link unprocessable
grve-20230930_lab.xml Edgar Link unprocessable
grve-20230930_def.xml Edgar Link unprocessable
eps11092_grve_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending